The incidence of infections caused by Candida species (referred to as candidiasis) has increased dramatically over the past decades, mainly owing to the rise of the HIV/AIDS epidemic, larger amounts of immunocompromised patients, and the more widespread use of indwelling medical devices. Nevertheless, the development of antifungal drugs has been relatively limited when compared with antibiotics. To address this, scientists at Creative Biolabs are committed to providing a comprehensive series of high-quality services for antifungal drug discovery against Candida tropicalis.
Introduction to Candida Tropicalis
Candida tropicalis (C. tropicalis) is a diploid yeast which belongs to the Candida spp. It is regarded as an osmotolerant yeast, which is identified as microorganism with the ability to survive in high salt concentration and to develop fungal persistence in saline environments. C. tropicalis has proved to be the most prevalent pathogenic yeast of the Candida-non-albicans group that cause human disease, particularly on human skin, in the gastrointestinal tract and also in the female genitourinary tract. It commonly infects neutropenic hosts, in whom it may spread through the bloodstream to peripheral organs. In addition, C. tropicalis can be transmitted between health-care workers and patients, especially in the hospital environment.
Fig.1 Candida tropicalis.
Pathogenesis of C. Tropicalis
Candidiasis caused by C. tropicalis has been increased globally. And recent data have shown that C. tropicalis is even more invasive than C. albicans in the human intestine, especially in oncology patients. C. tropicalis is able to generate true hyphae and has also been regarded as a strong biofilm producer species, which is highly adherent to epithelial and endothelial cells. The purified tropiase from C. tropicalis, a novel acid proteinase, has reported having hemorrhagic activity and the capacity to increase capillary permeability. Moreover, the virulence of C. tropicalis is also owing to its ability to form a biofilm, secrete lytic enzymes, undergo a transition of bud to hyphae, and adhere to epithelial as well as endothelial cells.
Antifungal Drugs against C. Tropicalis
There are various types of treatment for different levels of infections caused by C. tropicalis. Antifungal drugs are typically utilized to treat C. tropicalis infections, among those amphotericin B deoxycholates is the most common antifungal drug to be used. The high risk of severe infections caused by C. tropicalis has attracted great attention, especially considering the significant increase in its resistance to antifungal agents, which is a serious therapeutic issue. The resistance of C. tropicalis to azoles has been extensively demonstrated.
Antifungal Drug Discovery Services Against C. Tropicalis at Creative Biolabs
Creative Biolabs has been a key player in the antifungal drug discovery field for years and our scientists are devoting to facilitating your drug discovery research and expanding the influence of your projects. Our experienced scientists can assist you in preclinical drug through a variety of assays including:
Moreover, our services are characterized by several features as follows:
You may also be interested in other fungi that may be implicated in candidiasis:
If you are interested in our antifungal drug discovery services, please do not hesitate to contact us for more details.
For Research Use Only.
